Gestational MAM (Methylazoxymethanol) administration

A promising animal model for psychosis onset

Gwenaëlle Le Pen, Alfredo Bellon, Marie Odile Krebs, Thérèse M. Jay

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

This chapter provides an overview on exposure to methylazoxymethanol (MAM) at embryonic day 17 as a promising animal model for schizophrenia that mimics behavioral abnormalities and deficits in prefrontal cortex networks. This early insult produces in adult offspring from E17 MAM-treated dams the following: (1) behavioral changes including spontaneous hyperactivity and hypersensitivity to psychotomimetic drugs that are reminiscent of positive symptoms of schizophrenia and associated with a temporal pattern of expression; (2) impaired social interaction similar to that observed in schizophrenic patients existing prior to the onset of disease; (3) cognitive deficits in a variety of domain: working and reference memory, behavioral flexibility, attentional functioning, object recognition, and reversal learning; (4) behavioral abnormalities resembling schizophrenia-related endophenotypes like deficient sensorimotor gating and disrupted latent inhibition; (5) anatomical changes with cortical, thalamic, and hippocampal reductions in volume that are associated with an enlargement of the lateral ventricles; and (6) abnormalities in functional connectivity between brain areas that involve deficits in dopamine, glutamate, and GABA systems. The E17 MAM model that incorporates neuropathological and functional manifestations associated with schizophrenia may help forward early preventive interventions that can successfully reduce the risk of developing schizophrenia in exposed individuals.

Original languageEnglish
Title of host publicationNeuromethods
Pages25-77
Number of pages53
Volume59
DOIs
StatePublished - Jul 1 2011

Publication series

NameNeuromethods
Volume59
ISSN (Print)08932336
ISSN (Electronic)19406045

Fingerprint

Psychotic Disorders
Schizophrenia
Animals
Animal Models
Object recognition
gamma-Aminobutyric Acid
Dams
Reversal Learning
Glutamic Acid
Dopamine
Brain
Sensory Gating
Endophenotypes
Lateral Ventricles
Adult Children
Data storage equipment
Interpersonal Relations
Prefrontal Cortex
Short-Term Memory
Hypersensitivity

Keywords

  • anatomical and functional abnormalities
  • animal model
  • behavioral and cognitive deficits
  • hippocampus
  • MAM
  • prefrontal cortex
  • schizophrenia
  • schizophrenia-related endophenotypes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Le Pen, G., Bellon, A., Krebs, M. O., & Jay, T. M. (2011). Gestational MAM (Methylazoxymethanol) administration: A promising animal model for psychosis onset. In Neuromethods (Vol. 59, pp. 25-77). (Neuromethods; Vol. 59). https://doi.org/10.1007/978-1-61779-157-4_2

Gestational MAM (Methylazoxymethanol) administration : A promising animal model for psychosis onset. / Le Pen, Gwenaëlle; Bellon, Alfredo; Krebs, Marie Odile; Jay, Thérèse M.

Neuromethods. Vol. 59 2011. p. 25-77 (Neuromethods; Vol. 59).

Research output: Chapter in Book/Report/Conference proceedingChapter

Le Pen, G, Bellon, A, Krebs, MO & Jay, TM 2011, Gestational MAM (Methylazoxymethanol) administration: A promising animal model for psychosis onset. in Neuromethods. vol. 59, Neuromethods, vol. 59, pp. 25-77. https://doi.org/10.1007/978-1-61779-157-4_2
Le Pen G, Bellon A, Krebs MO, Jay TM. Gestational MAM (Methylazoxymethanol) administration: A promising animal model for psychosis onset. In Neuromethods. Vol. 59. 2011. p. 25-77. (Neuromethods). https://doi.org/10.1007/978-1-61779-157-4_2
Le Pen, Gwenaëlle ; Bellon, Alfredo ; Krebs, Marie Odile ; Jay, Thérèse M. / Gestational MAM (Methylazoxymethanol) administration : A promising animal model for psychosis onset. Neuromethods. Vol. 59 2011. pp. 25-77 (Neuromethods).
@inbook{c4a07d381fe64692b945c753fcce79c1,
title = "Gestational MAM (Methylazoxymethanol) administration: A promising animal model for psychosis onset",
abstract = "This chapter provides an overview on exposure to methylazoxymethanol (MAM) at embryonic day 17 as a promising animal model for schizophrenia that mimics behavioral abnormalities and deficits in prefrontal cortex networks. This early insult produces in adult offspring from E17 MAM-treated dams the following: (1) behavioral changes including spontaneous hyperactivity and hypersensitivity to psychotomimetic drugs that are reminiscent of positive symptoms of schizophrenia and associated with a temporal pattern of expression; (2) impaired social interaction similar to that observed in schizophrenic patients existing prior to the onset of disease; (3) cognitive deficits in a variety of domain: working and reference memory, behavioral flexibility, attentional functioning, object recognition, and reversal learning; (4) behavioral abnormalities resembling schizophrenia-related endophenotypes like deficient sensorimotor gating and disrupted latent inhibition; (5) anatomical changes with cortical, thalamic, and hippocampal reductions in volume that are associated with an enlargement of the lateral ventricles; and (6) abnormalities in functional connectivity between brain areas that involve deficits in dopamine, glutamate, and GABA systems. The E17 MAM model that incorporates neuropathological and functional manifestations associated with schizophrenia may help forward early preventive interventions that can successfully reduce the risk of developing schizophrenia in exposed individuals.",
keywords = "anatomical and functional abnormalities, animal model, behavioral and cognitive deficits, hippocampus, MAM, prefrontal cortex, schizophrenia, schizophrenia-related endophenotypes",
author = "{Le Pen}, Gwena{\"e}lle and Alfredo Bellon and Krebs, {Marie Odile} and Jay, {Th{\'e}r{\`e}se M.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1007/978-1-61779-157-4_2",
language = "English",
isbn = "9781617791567",
volume = "59",
series = "Neuromethods",
pages = "25--77",
booktitle = "Neuromethods",

}

TY - CHAP

T1 - Gestational MAM (Methylazoxymethanol) administration

T2 - A promising animal model for psychosis onset

AU - Le Pen, Gwenaëlle

AU - Bellon, Alfredo

AU - Krebs, Marie Odile

AU - Jay, Thérèse M.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - This chapter provides an overview on exposure to methylazoxymethanol (MAM) at embryonic day 17 as a promising animal model for schizophrenia that mimics behavioral abnormalities and deficits in prefrontal cortex networks. This early insult produces in adult offspring from E17 MAM-treated dams the following: (1) behavioral changes including spontaneous hyperactivity and hypersensitivity to psychotomimetic drugs that are reminiscent of positive symptoms of schizophrenia and associated with a temporal pattern of expression; (2) impaired social interaction similar to that observed in schizophrenic patients existing prior to the onset of disease; (3) cognitive deficits in a variety of domain: working and reference memory, behavioral flexibility, attentional functioning, object recognition, and reversal learning; (4) behavioral abnormalities resembling schizophrenia-related endophenotypes like deficient sensorimotor gating and disrupted latent inhibition; (5) anatomical changes with cortical, thalamic, and hippocampal reductions in volume that are associated with an enlargement of the lateral ventricles; and (6) abnormalities in functional connectivity between brain areas that involve deficits in dopamine, glutamate, and GABA systems. The E17 MAM model that incorporates neuropathological and functional manifestations associated with schizophrenia may help forward early preventive interventions that can successfully reduce the risk of developing schizophrenia in exposed individuals.

AB - This chapter provides an overview on exposure to methylazoxymethanol (MAM) at embryonic day 17 as a promising animal model for schizophrenia that mimics behavioral abnormalities and deficits in prefrontal cortex networks. This early insult produces in adult offspring from E17 MAM-treated dams the following: (1) behavioral changes including spontaneous hyperactivity and hypersensitivity to psychotomimetic drugs that are reminiscent of positive symptoms of schizophrenia and associated with a temporal pattern of expression; (2) impaired social interaction similar to that observed in schizophrenic patients existing prior to the onset of disease; (3) cognitive deficits in a variety of domain: working and reference memory, behavioral flexibility, attentional functioning, object recognition, and reversal learning; (4) behavioral abnormalities resembling schizophrenia-related endophenotypes like deficient sensorimotor gating and disrupted latent inhibition; (5) anatomical changes with cortical, thalamic, and hippocampal reductions in volume that are associated with an enlargement of the lateral ventricles; and (6) abnormalities in functional connectivity between brain areas that involve deficits in dopamine, glutamate, and GABA systems. The E17 MAM model that incorporates neuropathological and functional manifestations associated with schizophrenia may help forward early preventive interventions that can successfully reduce the risk of developing schizophrenia in exposed individuals.

KW - anatomical and functional abnormalities

KW - animal model

KW - behavioral and cognitive deficits

KW - hippocampus

KW - MAM

KW - prefrontal cortex

KW - schizophrenia

KW - schizophrenia-related endophenotypes

UR - http://www.scopus.com/inward/record.url?scp=79959641618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959641618&partnerID=8YFLogxK

U2 - 10.1007/978-1-61779-157-4_2

DO - 10.1007/978-1-61779-157-4_2

M3 - Chapter

SN - 9781617791567

VL - 59

T3 - Neuromethods

SP - 25

EP - 77

BT - Neuromethods

ER -